Close

GD2-0-acctylated

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

GM2 and GD2 gangliosides are sialic acid-containing glycosphingolipids. GalNAc-T is the enzyme involved in the biosynthesis of G(M2) and G(D2) glycosphingolipids. GalNAc-T catalyzes the transfer of GalNAc into G(M3) and G(D3) by a beta-1,4 linkage, resulting in the synthesis of G(M2) and G(D2), respectively. Three transcript variants encoding different isoforms have been found for this gene.
  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-YF213 Anti-GD2-0-acctylated (KM8B6) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human KM8B6 Humanized scFv-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF214 Anti-GD2-0-acctylated (KM8B6) h(CD28-CD3ζ) CAR, pCDCAR1 Human KM8B6 Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF215 Anti-GD2-0-acctylated (8B6) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human 8B6 Humanized scFv-4-1BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YF216 Anti-GD2-0-acctylated (8B6) h(CD28-CD3ζ) CAR, pCDCAR1 Human 8B6 Humanized scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.